Grünenthal USA Inc.
Partner in Pain Management
Grünenthal USA is a subsidiary of Grünenthal GmbH, an independent, family-owned pharmaceutical company specializing in pain management.
Grünenthal USA partners with other leading pharmaceutical companies to deliver innovative products to patients living with pain.
Grünenthal USA, Inc.
360 Mount Kemble Avenue
Morristown, NJ 07960
Grünenthal has acquired US-based Thar Pharmaceuticals Inc.
Development portfolio expansion of treatment options for CRPS (Complex Regional Pain Syndrome)
Grünenthal has announced its recent acquisition of Thar Pharmaceuticals, a US-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical’s lead development candidate, T121.